We talk a lot about the treatment of relapsing-remitting MSM but we really want to develop more treatment options for progressive MS.
Dirucotide (MBP8298) is being studied in clinical trials for the treatment of secondary progressive MS (SPMS) at 68 sites with approximately 510 patients. The FDA has given fast track status because of the potential to do good for people with SPMS as it has the potential to address unmet medical needs. Fast track designation can potentially facilitate...
